Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Clinical Trial

EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Benzinga

Chinese Omicron-specific mRNA COVID vaccine candidate to be trialed in UAE

China's Suzhou Abogen Biosciences Co said its COVID-19 vaccine candidate using the messenger RNA (mRNA) technology and targeting the Omicron variant has obtained clinical trial approval in the United Arab Emirates.

Reuters

How To Enroll In A Psychedelic Clinical Trial In 5 Easy Steps

This article was originally published on Psychedelic Spotlight and appears here with permission. If you fail to meet even one of the inclusion criteria, or you meet even one of the exclusion criteria, then you are not eligible and you will not be selected for participation.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer, BioNTech Seeks Emergency Use Nod For COVID-19 Vaccine For Kids 5-11 Years

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have submitted an FDA Emergency Use Authorization (EUA) application for a 10-µg booster dose of COVID-19 Vaccine for children 5 through 11 years of age. The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose…

Benzinga

Jasper Therapeutics Presented Updated Data from Phase 1 Clinical Trial of JSP191

Jasper Therapeutics, Inc., (NASDAQ: JSPR) announced updated efficacy, safety and pharmacokinetic data from its Phase 1 clinical trial of JSP191, in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.

Benzinga

Biomind Begins Clinical Trial For Inhaled DMT Analog Substance To Treat Depression

Biomind Labs (OTCQB:BMNDF) has begun administering its proprietary second-generation psychedelic, BMND01, in a Phase 1/2a clinical trial for treatment-resistant depression (TRD).

Benzinga

Phio Pharmaceuticals Open enrollment in Phase 1b Trial of PH-762 for the Treatment of Advanced Melanoma

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has started enrolling patients in the Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Monash IVF Group's 'inaccurate' genetic test potentially robbed these women of viable embryos

IVF is big business in Australia. But in the quest to innovate, one company may have gone too far.

ABC News

Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp

Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to it

Benzinga

Boy who started feeling sick after returning to school handed life-threatening diagnosis

Tom, 14, is battling a cancerous brain tumour and has been told there is nothing more doctors can do, sparking a GoFundMe page to find a clinical trial in another country

Daily Mirror

Paving the way for a global malaria vaccine

Malaria impacts India more than anywhere else in southeast Asia, but relief could be on the way if the early promise of vaccines in development is fulfilled.

360info

The Bedaquiline Question

One of the increasingly contentious public health issues in India is the manner in which clinical trials are conducted for new drugs and the manner in which these new drugs are subsequently approved for use on Indian patients.

Newslaundry

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

Psychedelic Spotlight

29 stories

PfizerBioNTech

26 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.